Core Insights - Novo Nordisk's CEO Mike Doustdar highlighted that up to 1.5 million patients in the U.S. may be using compounded versions of GLP-1 drugs, indicating a significant market for cheaper, unapproved alternatives [1] Company Summary - The mention of 1.5 million patients suggests a substantial demand for GLP-1 drugs, which are known for their effectiveness in treating conditions like obesity and diabetes [1] - The existence of compounded versions points to a potential challenge for Novo Nordisk, as these alternatives may impact the sales of their approved products [1] Industry Summary - The trend of patients opting for compounded drugs reflects broader issues in the pharmaceutical industry regarding drug pricing and accessibility [1] - The rise of unapproved alternatives may lead to increased scrutiny and regulatory discussions surrounding the approval processes for such medications [1]

Group 1: Fundsmith Equity Fund Performance - Fundsmith Equity Fund's T Class Accumulation shares returned 0.8% in 2025, underperforming the MSCI World Index which returned 12.8% [1] - Since inception, the fund has outperformed the index by 1.7% per annum [1] - The underperformance in 2025 is attributed to index concentration, growth of assets in Index Funds, and weakness in the dollar [1] Group 2: Novo Nordisk A/S Overview - Novo Nordisk A/S had a one-month return of 16.76% but lost 30.50% of its value over the last 52 weeks [2] - As of January 9, 2026, Novo Nordisk A/S stock closed at $58.81 per share, with a market capitalization of $263.8 billion [2] - Fundsmith Equity Fund expressed concerns about Novo Nordisk's market position and its failure to prevent illegal generic competition in the US market [3] Group 3: Analyst Insights on Novo Nordisk A/S - Berenberg lowered the price target for Novo Nordisk A/S to DKK 400 while maintaining a Buy rating [4] - The stock is not among the 30 Most Popular Stocks Among Hedge Funds, with 50 hedge fund portfolios holding it at the end of Q3, up from 45 in the previous quarter [4] - Analysts suggest that certain AI stocks may offer greater upside potential and less downside risk compared to Novo Nordisk A/S [4]

Core Viewpoint - The performance of Fundsmith Equity Fund in 2025 was disappointing, with an annual increase of only 0.8%, significantly lagging behind the MSCI World Index, which rose by 12.8% [2][11]. Performance Overview - Fundsmith Equity Fund's cumulative return since inception is 612.9%, with an annualized return of 13.8%, outperforming the MSCI World Index by 1.7 percentage points [10][11]. - The Sortino Ratio for Fundsmith is 0.75, indicating a higher return per unit of downside risk compared to the index's 0.48 [11]. Key Factors Affecting Performance - **Concentration of Index**: The dominance of a few large tech stocks, referred to as the "Seven Giants," has significantly influenced market returns, with the top ten stocks contributing 50% of the S&P 500's total return by the end of 2025 [16][19][22]. - **Growth of Index Fund Assets**: The expansion of passive index funds has created a momentum effect, where funds are automatically allocated to the highest-weighted stocks, further driving up their prices [24][26][28]. - **Weakening Dollar**: The dollar weakened against the pound in 2025, impacting the performance of Fundsmith, which primarily invests in U.S. companies [34]. Notable Holdings - **Novo Nordisk**: This stock was the largest detractor from performance, with a nearly 40% decline in 2025, attributed to execution and governance failures rather than the product direction [3][4][5][41]. - **Top Contributors**: Alphabet, IDEXX, Philip Morris, Meta Platforms, and Microsoft were the top contributors to the fund's performance in 2025, with Alphabet making its first appearance on the list [45][46]. Investment Strategy - The company maintains a three-step investment strategy: buy good companies, avoid overpaying, and do nothing [48]. - The focus remains on holding high-quality companies with sustainable growth, as evidenced by a 16% increase in free cash flow across the portfolio [53]. Changes in Portfolio - The company sold positions in Brown-Forman and PepsiCo due to concerns over the impact of weight-loss drugs on consumer behavior, while initiating positions in Zoetis, EssilorLuxottica, Intuit, and Wolters Kluwer [64][66]. Conclusion - The company aims to continue holding a portfolio of high-quality businesses, expecting that solid fundamentals will eventually reflect in better stock performance and long-term fund results [67].

Investment Rating - The report indicates a positive investment outlook for the pharmaceutical sector, with the overall performance of the Shenwan Pharmaceutical and Biological Index increasing by 7.8% during the week, outperforming the Shanghai Composite Index which rose by 3.82% [2][3]. Core Insights - The pharmaceutical sector's overall valuation stands at 30.6 times earnings, ranking 10th among 31 Shenwan primary industries [5]. - The report highlights significant developments in the long-term care insurance system transitioning from pilot programs to full establishment during the 14th Five-Year Plan, with coverage reaching nearly 300 million people and fund expenditures exceeding 100 billion yuan by the end of 2025 [11]. - Notable advancements in drug commercialization include the launch of Novo Nordisk's oral GLP-1 weight loss drug Wegovy in the U.S., with monthly costs ranging from $149 to $299 for self-paying patients [13][14]. - Moderna has submitted a New Drug Application (NDA) for its seasonal flu vaccine mRNA-1010, showing promising efficacy results in clinical trials [15]. - Arrowhead has reported positive mid-stage results for its RNAi therapies ARO-INHBE and ARO-ALK7, demonstrating significant reductions in visceral and liver fat [16][17]. - GSK's hepatitis B drug Bepirovirsen has shown statistically significant functional cure rates in its Phase III trials [18]. - Recent approvals for innovative drugs in China include BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which addresses familial chylomicronemia syndrome [19][21]. Summary by Sections Market Performance - The Shenwan Pharmaceutical and Biological Index increased by 7.8%, ranking 6th among 31 Shenwan primary industries [2][3]. - Various sub-sectors showed positive growth, with medical devices and medical outsourcing leading with increases of 10.8% and 11.1%, respectively [5]. Industry Dynamics - The long-term care insurance system is set to expand significantly, with a focus on providing care for the elderly and disabled [11][12]. - The report emphasizes the importance of innovation in drug development, particularly in RNAi therapies and small nucleic acid drugs, which are gaining traction in clinical settings [16][18]. Company Developments - Significant partnerships and collaborations are highlighted, such as the $8.88 billion research collaboration between Insilico Medicine and Servier focusing on oncology [20]. - The report notes the successful commercialization of several new drugs, including BeiGene's and Sanofi's recent approvals, which are expected to impact market dynamics positively [19][21]. - The establishment of new companies and subsidiaries, such as the brain-computer interface subsidiary by Xinwei Medical, indicates a strategic shift towards innovative technologies in healthcare [22].

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, indicating a "Buy" rating based on recent market performance and emerging opportunities in innovative drug development [2][3]. Core Insights - The pharmaceutical sector saw a significant increase, with the Shenwan Pharmaceutical and Biological Index rising by 7.8%, outperforming the Shanghai Composite Index, which increased by 3.82% [2][3]. - The report highlights the ongoing commercialization of innovative drugs, including the oral GLP-1 medication Wegovy by Novo Nordisk, and the successful clinical trials of various RNAi therapies [11][13][18]. - The establishment of a comprehensive long-term care insurance system in China is expected to enhance the healthcare landscape, potentially benefiting the pharmaceutical sector [11][12]. Market Performance - The Shenwan Pharmaceutical and Biological Index ranked 6th among 31 Shenwan first-level sub-industries, with various sub-sectors showing positive growth, such as medical devices (+10.8%) and medical research outsourcing (+11.1%) [2][5]. - The overall valuation of the pharmaceutical sector stands at 30.6 times earnings, ranking 10th among 31 Shenwan first-level industries [5][10]. Recent Key Events - The report notes the successful approval and commercialization of several new drugs, including BeiGene's BCL-2 inhibitor and Sanofi's APOC3 siRNA drug, which address significant medical needs [20][22]. - Collaborations in drug development are highlighted, such as the $8.88 billion partnership between Insilico Medicine and Servier focusing on oncology [21]. - The report emphasizes the potential of the brain-computer interface industry, with companies like Mindray Medical and Lepu Medical making strides in this area [24]. Investment Opportunities - The report suggests focusing on domestic innovative drug companies and CROs, particularly those involved in the development of small nucleic acid drugs and brain-computer interface technologies [2][11]. - Specific companies to watch include Tigermed, WuXi AppTec, and Innovent Biologics, which are positioned to benefit from the recovery of the innovative drug sector [2][11].

Core Insights - The healthcare sector underperformed the broader market last year, with notable losses from companies like UnitedHealth Group, Elevance Health, and Novo Nordisk, but has recently shown a turnaround with a nearly 19% gain over the past six months, leading all sectors of the S&P 500 [2][6] Group 1: Sector Performance - The healthcare sector had gains of only 2.6% in 2024, 2.1% in 2023, and a loss of 2.0% in 2022, failing to outperform the market [2] - Over the past six months, healthcare stocks have led the S&P 500 with a nearly 19% gain, indicating a potential recovery [2][6] Group 2: Catalysts for Growth - Two major catalysts are driving the bullish momentum in healthcare stocks: the mass adoption of weight loss drugs and comparatively low valuations, which may attract further investments [4] - The GLP-1 drug market is projected to grow at a compound annual growth rate of 18.54% from 2024 to 2030, increasing its global market value from $13.84 billion to $48.84 billion [7] Group 3: Weight Loss Treatment Trends - Weight loss treatments, particularly GLP-1 agonists and semaglutide products like Ozempic and Wegovy, are gaining widespread adoption, with pharmaceutical companies shifting towards more accessible pill forms [5][6] - The popularity of these drugs is expected to continue, with industry experts suggesting that they may become ubiquitous in daily life [6]

Core Viewpoint - Novo Nordisk's GLP-1 receptor agonist, Ozempic® (semaglutide injection), has received approval from the National Medical Products Administration (NMPA) in China for an updated label that includes benefits for patients with peripheral artery disease (PAD) [4] Group 1: Clinical Trial Results - The update is based on the STRIDE clinical trial results, which demonstrated that Ozempic® 1.0mg significantly improves walking ability in patients with type 2 diabetes and PAD, increasing the maximum walking distance by 13% and showing an average treatment difference of 39.9 meters [4] Group 2: Treatment Options - Type 2 diabetes is a primary risk factor for PAD, with nearly one-third of PAD patients also having type 2 diabetes. Currently, there are limited treatment options specifically aimed at improving walking ability in this population, making the updated label for Ozempic® a new treatment choice for these patients [5] Group 3: Progress of Ozempic® in China - Since its launch, Ozempic® has progressed through various indications in China, receiving dual indications for glycemic control and cardiovascular event reduction in 2021, becoming the first and only GLP-1 RA weekly formulation with cardiovascular indications in the country. It was included in the national medical insurance the same year [6] - By July 2025, it will gain an additional indication for chronic kidney disease, making it the first GLP-1 drug in China with three indications: diabetes, cardiovascular, and kidney [6] - The inclusion of PAD benefits marks an upgrade in its "multiple protections" for Chinese patients [6]

Group 1 - Amazon Pharmacy has announced the availability of Novo Nordisk's Wegovy pill for eligible customers with commercial insurance at a cost as low as $25 for a one-month supply [1] - For customers without insurance, the Wegovy pill will be available through a cash-pay option starting at $149 per month [1] - Amazon Pharmacy offers fast home delivery of the pill to all 50 states and plans to make it available through its Kiosks in the coming weeks [1]

Core Insights - The "High-Income DIY Portfolios" Marketplace service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees or near-retirees [1][2] - The service offers a total of 10 model portfolios, including 3 buy-and-hold, 3 rotational portfolios, and a conservative NPP strategy portfolio, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1 - The service includes two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy portfolio that focuses on low drawdowns and high growth [1] - The unique 3-basket investment approach aims for 30% lower drawdowns, 6% current income, and market-beating growth over the long term [2] - The portfolios are structured to cater to varying levels of risk and include buy and sell alerts along with live chat support for investors [2]

Core Insights - The GLP-1 market is transitioning from weekly injections to daily oral pills, with Novo Nordisk's Wegovy pill already available and Eli Lilly's expected soon, indicating a significant shift in obesity treatment options [1][7][30] Market Dynamics - The introduction of oral GLP-1 pills is expected to attract new patients, particularly those who prefer pills over injections, potentially expanding the obesity treatment market significantly [4][8] - Goldman Sachs analysts project that oral pills could capture approximately 24% of the global weight-loss drug market by 2030, equating to about $22 billion [7][30] Pricing and Accessibility - Novo Nordisk's Wegovy pill is priced between $149 and $299 per month, making it a more affordable option compared to the cash prices of injections, which have been reduced to around $349 per month [2][13][15] - Patients with insurance may pay as little as $25 per month for the oral drug, although overall insurance coverage for GLP-1s remains uncertain [16][18] Patient Preferences - Many patients may prefer pills due to convenience and lower costs, with some expressing interest in switching from injections to oral medications [5][12][24] - The convenience of oral medications may appeal to those who are needle-averse or do not perceive their condition as severe enough to warrant injections [4][10] Competitive Landscape - Eli Lilly's oral GLP-1 is anticipated to be more convenient due to its absorption characteristics and lack of dietary restrictions compared to Novo Nordisk's pill [25][30] - Other pharmaceutical companies, including Pfizer and AstraZeneca, are also developing oral GLP-1 options, indicating a competitive race in the market [31][33] Efficacy and Treatment Options - Clinical trials suggest that while pills may not provide greater weight loss than injections, they could still be effective for patients seeking modest weight loss [3][21] - The highest dose of Novo Nordisk's Wegovy pill resulted in an average weight loss of 16.6% over 64 weeks, comparable to its injectable form [28]